Analysis on pre-antiretroviral treatment drug resistance in people infected with HIV-1CRF08_BC in China,2004-2022
Objective To investigate the pre-antiretroviral treatment resistance to protease inhibitors(PIs),nucleoside reverse transcriptase inhibitors(NRTIs),and non-nucleoside reverse transcriptase inhibitors(NNRTIs)in people infected with HIV-1 CRF08_BC in China.Methods From national HIV drug resistance survey database and HIV database of China and Los Alamos HIV gene database,HIV-1 CRF08_BC sequences were selected in pre-antiretroviral treatment samples collected between 2004 and 2022.Drug resistance was analyzed by using Stanford HIVdb Program.Molecular transmission networks were constructed by using software HIV-TRACE.Results A total of 4 539 HIV-1 CRF08_BC sequences were included,and the overall drug resistance rate was 15.27％(693/4 539).The resistance rates to PIs,NRTIs and NNRTIs were 1.70％(77/4 539),1.85％(84/4 539),and 12.91％(586/4 539),respectively.In which the resistance rate to rilpivirine was highest(11.28％,512/4 539).The rate of multi-drug resistance was 0.1％(44/4 539).Conclusion In recent years,the drug resistance rate in HIV-1 CRF08_BC-infected patients increased in China,which could be explained by increased resistance to NNRTIs,in which the resistance rate to rilpivirine was highest.The transmission of drug-resistant strains exists in China,indicating that pre-antiretroviral treatment drug resistance on antiretroviral therapy needs to be further monitored and analyzed.
Human immunodeficiency virusCRF08_BC subtypePre-antiretroviral treatmentTransmitted drug resistanceDrug resistance mutation
NETL
NSTL
万方数据
